Population pharmacokinetic modeling of caffeine in preterm infants with apnea of prematurity: New findings from concomitant erythromycin and AHR genetic polymorphisms

Precision caffeine therapy for apnea of prematurity and circadian rhythms: New possibilities open up

“…The optimal dose regimen, timing and duration of therapy, necessity of therapeutic drug monitoring, and variable clinical outcomes of caffeine in preterm infants remain controversial ( Gentle et al, 2018 ; Davis, 2020 ; Saroha and Patel, 2020 ). Impressively, however, those problems related to the clinical use of caffeine in preterm infants have been widely concerned and discussed as the continuous deepening of research, especially as the application of several innovative research technologies, such as artificial intelligence, predictive modeling, and machine learning ( Koch et al, 2017 ; Shirwaikar, 2018 ; Faramarzi et al, 2021 ; Dai et al, 2022 ). Interestingly, several novel findings in those studies provide valuable references for determining the optimal initial dose, tailoring the maintenance dose, enhancing clinical decision making, and then for promoting the achievement of consensus on those tough challenges ( Abdel-Hady et al, 2015 ; Eichenwald, 2020 ; Moschino et al, 2020 ).…”